index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

74

 

NOTICES

154

 

 

MOTS CLES

Anticancer drugs Antimicrobial resistance Stability Auto-immune hepatitis Biological therapy Cardiovascular risk Placebo Alitretinoin Aging Adverse side effects Cessation Endocrine toxicity Addiction Management Angiotensin-converting enzyme inhibitors Acute Myeloid Leukaemia AML Biologic therapy Antibiotic misuse Bacterial rhinosinusitis Auto-Diagnostic Cardiotoxicity Adolescent Autoimmunity Intensive care Angiotensin receptor blockers Anti-TNF Biologics Sipuleucel-T Antibiotics CTLA-4 Case-Control Studies Access to care Albinism Méta-Analyse Abus d'antibiotiques Calcium channel blockers Atrial fibrillation Glucocorticoids Immune-related adverse events Graft-versus-host disease Burden Beta-lactam antibiotics Cardio-oncology Primary adrenal insufficiency Spondyloarthritis Apre-milast Azathioprine Atopic dermatitis Infliximab Biomarkers Apremilast COVID-19 Causality BTK protein Biologic Ankylosing spondylitis Adalimumab Drug reaction Antimicrobiens ASDAS Epidemiology Cancer Cardiovascular therapy Cardiomyopathy Chemotherapy Arrhythmia Cessation aids Cattle Anti-HCV Direct Acting Antivirals DAA Axial spondyloarthritis Vigibase® Arthritis Antimicrobials Quality of life Care pathway Pharmacovigilance Ustekinumab Psoriasis Etanercept Accelerometer Prostate cancer Amyloidosis Antibiotic resistance Pharmacoepidemiology Immune checkpoint inhibitors Dermatology ArtThese Biologic drug CSK tyrosine-protein kinase Ethics Psoriatic arthritis Causality Background Meta-Analysis Alcohol Sacroiliitis Autoimmune diseases Immunotherapy Biomédicaments Drug survival Treatment

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS